Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Growth 2022-2028

  • LP 4752904
  • 103 Pages
  • January 2022
  • Pharmaceuticals
Download Sample    Get Discount   
 
As the global economy mends, the 2021 growth of Angiotensin Converting Enzyme (ACE) Inhibitors will have significant change from previous year. According to our (LP Information) latest study, the global Angiotensin Converting Enzyme (ACE) Inhibitors market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Angiotensin Converting Enzyme (ACE) Inhibitors market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Angiotensin Converting Enzyme (ACE) Inhibitors market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Angiotensin Converting Enzyme (ACE) Inhibitors market, reaching US$ million by the year 2028. As for the Europe Angiotensin Converting Enzyme (ACE) Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Angiotensin Converting Enzyme (ACE) Inhibitors players cover Abbott Laboratories, Pfizer, Novartis, and Merck, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Converting Enzyme (ACE) Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

Sulfhydryl-containing Agents

Dicarboxylate-containing Agents

Phosphonate-containing Agents

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Hypertension

Cardiovascular Diseases

Kidney Diseases

Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

Abbott Laboratories

Pfizer

Novartis

Merck

Astra Zeneca

Jhonson and Johnson

Eli Lilly

Sanofi

Bristol-Myers Squibb

Bayer

GSK

Teva Pharmaceutical

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Country/Region, 2017, 2022 & 2028

2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type

2.2.1 Sulfhydryl-containing Agents

2.2.2 Dicarboxylate-containing Agents

2.2.3 Phosphonate-containing Agents

2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

2.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

2.3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue and Market Share by Type (2017-2022)

2.3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Type (2017-2022)

2.4 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application

2.4.1 Hypertension

2.4.2 Cardiovascular Diseases

2.4.3 Kidney Diseases

2.4.4 Other

2.5 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

2.5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Market Share by Application (2017-2022)

2.5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue and Market Share by Application (2017-2022)

2.5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Application (2017-2022)

3 Global Angiotensin Converting Enzyme (ACE) Inhibitors by Company

3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Breakdown Data by Company

3.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Company (2020-2022)

3.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Company (2020-2022)

3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Company (2020-2022)

3.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Company (2020-2022)

3.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company (2020-2022)

3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Company

3.4 Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Product Location Distribution

3.4.2 Players Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region

4.1 World Historic Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Geographic Region (2017-2022)

4.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Geographic Region

4.2 World Historic Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country/Region (2017-2022)

4.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Country/Region (2017-2022)

4.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Country/Region

4.3 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth

4.4 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth

4.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth

4.6 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth

5 Americas

5.1 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country

5.1.1 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022)

5.1.2 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022)

5.2 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

5.3 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region

6.1.1 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2017-2022)

6.1.2 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2017-2022)

6.2 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

6.3 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors by Country

7.1.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022)

7.1.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022)

7.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

7.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors by Country

8.1.1 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022)

8.1.2 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022)

8.2 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

8.3 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

10.3 Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

10.4 Industry Chain Structure of Angiotensin Converting Enzyme (ACE) Inhibitors

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors

11.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customer

12 World Forecast Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region

12.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Forecast by Region

12.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Region (2023-2028)

12.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Type

12.7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Application

13 Key Players Analysis

13.1 Abbott Laboratories

13.1.1 Abbott Laboratories Company Information

13.1.2 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Abbott Laboratories Main Business Overview

13.1.5 Abbott Laboratories Latest Developments

13.2 Pfizer

13.2.1 Pfizer Company Information

13.2.2 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Pfizer Main Business Overview

13.2.5 Pfizer Latest Developments

13.3 Novartis

13.3.1 Novartis Company Information

13.3.2 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Novartis Main Business Overview

13.3.5 Novartis Latest Developments

13.4 Merck

13.4.1 Merck Company Information

13.4.2 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Merck Main Business Overview

13.4.5 Merck Latest Developments

13.5 Astra Zeneca

13.5.1 Astra Zeneca Company Information

13.5.2 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Astra Zeneca Main Business Overview

13.5.5 Astra Zeneca Latest Developments

13.6 Jhonson and Johnson

13.6.1 Jhonson and Johnson Company Information

13.6.2 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Jhonson and Johnson Main Business Overview

13.6.5 Jhonson and Johnson Latest Developments

13.7 Eli Lilly

13.7.1 Eli Lilly Company Information

13.7.2 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.7.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Eli Lilly Main Business Overview

13.7.5 Eli Lilly Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

13.8.2 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Sanofi Main Business Overview

13.8.5 Sanofi Latest Developments

13.9 Bristol-Myers Squibb

13.9.1 Bristol-Myers Squibb Company Information

13.9.2 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Bristol-Myers Squibb Main Business Overview

13.9.5 Bristol-Myers Squibb Latest Developments

13.10 Bayer

13.10.1 Bayer Company Information

13.10.2 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Bayer Main Business Overview

13.10.5 Bayer Latest Developments

13.11 GSK

13.11.1 GSK Company Information

13.11.2 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.11.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 GSK Main Business Overview

13.11.5 GSK Latest Developments

13.12 Teva Pharmaceutical

13.12.1 Teva Pharmaceutical Company Information

13.12.2 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

13.12.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Teva Pharmaceutical Main Business Overview

13.12.5 Teva Pharmaceutical Latest Developments

14 Research Findings and Conclusion

List of Tables

Table 1. Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Sulfhydryl-containing Agents

Table 4. Major Players of Dicarboxylate-containing Agents

Table 5. Major Players of Phosphonate-containing Agents

Table 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2017-2022) & (K MT)

Table 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

Table 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2017-2022) & ($ million)

Table 9. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2017-2022)

Table 10. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Type (2017-2022) & (USD/Unit)

Table 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2017-2022) & (K MT)

Table 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Table 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2017-2022)

Table 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2017-2022)

Table 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Application (2017-2022) & (USD/Unit)

Table 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Company (2020-2022) & (K MT)

Table 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Company (2020-2022)

Table 18. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Company (2020-2022) ($ Millions)

Table 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company (2020-2022)

Table 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Company (2020-2022) & (USD/Unit)

Table 21. Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Producing Area Distribution and Sales Area

Table 22. Players Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered

Table 23. Angiotensin Converting Enzyme (ACE) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Geographic Region (2017-2022) & (K MT)

Table 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Geographic Region (2017-2022)

Table 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Geographic Region (2017-2022) & ($ millions)

Table 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Geographic Region (2017-2022)

Table 30. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country/Region (2017-2022) & (K MT)

Table 31. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country/Region (2017-2022)

Table 32. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country/Region (2017-2022) & ($ millions)

Table 33. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country/Region (2017-2022)

Table 34. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022) & (K MT)

Table 35. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2017-2022)

Table 36. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022) & ($ Millions)

Table 37. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2017-2022)

Table 38. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2017-2022) & (K MT)

Table 39. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

Table 40. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2017-2022) & (K MT)

Table 41. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Table 42. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2017-2022) & (K MT)

Table 43. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2017-2022)

Table 44. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2017-2022) & ($ Millions)

Table 45. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2017-2022)

Table 46. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2017-2022) & (K MT)

Table 47. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

Table 48. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2017-2022) & (K MT)

Table 49. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Table 50. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022) & (K MT)

Table 51. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2017-2022)

Table 52. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022) & ($ Millions)

Table 53. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2017-2022)

Table 54. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2017-2022) & (K MT)

Table 55. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

Table 56. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2017-2022) & (K MT)

Table 57. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2017-2022) & (K MT)

Table 59. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2017-2022) & ($ Millions)

Table 61. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2017-2022) & (K MT)

Table 63. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2017-2022) & (K MT)

Table 65. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Angiotensin Converting Enzyme (ACE) Inhibitors

Table 67. Key Market Challenges & Risks of Angiotensin Converting Enzyme (ACE) Inhibitors

Table 68. Key Industry Trends of Angiotensin Converting Enzyme (ACE) Inhibitors

Table 69. Angiotensin Converting Enzyme (ACE) Inhibitors Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List

Table 72. Angiotensin Converting Enzyme (ACE) Inhibitors Customer List

Table 73. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Region (2023-2028) & (K MT)

Table 74. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Forecast by Region

Table 75. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)

Table 76. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2023-2028) & (K MT)

Table 78. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)

Table 79. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Region (2023-2028) & (K MT)

Table 80. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2023-2028) & (K MT)

Table 82. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)

Table 83. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2023-2028) & (K MT)

Table 84. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Type (2023-2028) & (K MT)

Table 86. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 88. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Application (2023-2028) & (K MT)

Table 90. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 92. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Application (2023-2028)

Table 93. Abbott Laboratories Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 94. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 95. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 96. Abbott Laboratories Main Business

Table 97. Abbott Laboratories Latest Developments

Table 98. Pfizer Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 99. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 100. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 101. Pfizer Main Business

Table 102. Pfizer Latest Developments

Table 103. Novartis Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 104. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 105. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 106. Novartis Main Business

Table 107. Novartis Latest Developments

Table 108. Merck Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 109. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 110. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 111. Merck Main Business

Table 112. Merck Latest Developments

Table 113. Astra Zeneca Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 114. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 115. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 116. Astra Zeneca Main Business

Table 117. Astra Zeneca Latest Developments

Table 118. Jhonson and Johnson Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 119. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 120. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 121. Jhonson and Johnson Main Business

Table 122. Jhonson and Johnson Latest Developments

Table 123. Eli Lilly Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 124. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 125. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 126. Eli Lilly Main Business

Table 127. Eli Lilly Latest Developments

Table 128. Sanofi Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 129. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 130. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 131. Sanofi Main Business

Table 132. Sanofi Latest Developments

Table 133. Bristol-Myers Squibb Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 134. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 135. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 136. Bristol-Myers Squibb Main Business

Table 137. Bristol-Myers Squibb Latest Developments

Table 138. Bayer Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 139. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 140. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 141. Bayer Main Business

Table 142. Bayer Latest Developments

Table 143. GSK Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 144. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 145. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 146. GSK Main Business

Table 147. GSK Latest Developments

Table 148. Teva Pharmaceutical Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 149. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered

Table 150. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 151. Teva Pharmaceutical Main Business

Table 152. Teva Pharmaceutical Latest Developments

List of Figures

Figure 1. Picture of Angiotensin Converting Enzyme (ACE) Inhibitors

Figure 2. Angiotensin Converting Enzyme (ACE) Inhibitors Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate 2017-2028 (K MT)

Figure 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Sulfhydryl-containing Agents

Figure 10. Product Picture of Dicarboxylate-containing Agents

Figure 11. Product Picture of Phosphonate-containing Agents

Figure 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type in 2021

Figure 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2017-2022)

Figure 14. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Hypertension

Figure 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Hypertension (2017-2022) & (K MT)

Figure 16. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Cardiovascular Diseases

Figure 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Cardiovascular Diseases (2017-2022) & (K MT)

Figure 18. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Kidney Diseases

Figure 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Kidney Diseases (2017-2022) & (K MT)

Figure 20. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Other

Figure 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Other (2017-2022) & (K MT)

Figure 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2017-2022)

Figure 23. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application in 2021

Figure 24. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market by Company in 2021 ($ Million)

Figure 25. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company in 2021

Figure 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Geographic Region (2017-2022)

Figure 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Geographic Region in 2021

Figure 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2017-2022)

Figure 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country/Region in 2021

Figure 30. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2017-2022 (K MT)

Figure 31. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2017-2022 ($ Millions)

Figure 32. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2017-2022 (K MT)

Figure 33. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2017-2022 ($ Millions)

Figure 34. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2017-2022 (K MT)

Figure 35. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2017-2022 ($ Millions)

Figure 36. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2017-2022 (K MT)

Figure 37. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2017-2022 ($ Millions)

Figure 38. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2021

Figure 39. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2021

Figure 40. United States Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 41. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 42. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 43. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 44. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region in 2021

Figure 45. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Regions in 2021

Figure 46. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 47. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 48. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 49. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 50. India Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 51. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 52. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2021

Figure 53. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2021

Figure 54. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 55. France Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 56. UK Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 57. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 58. Russia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 59. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2021

Figure 60. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2021

Figure 61. Egypt Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 62. South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 63. Israel Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 64. Turkey Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 65. GCC Country Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2017-2022 ($ Millions)

Figure 66. Manufacturing Cost Structure Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors in 2021

Figure 67. Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

Figure 68. Industry Chain Structure of Angiotensin Converting Enzyme (ACE) Inhibitors

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025

The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...

  • Publish Date: June 24, 2019
  • $1050
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts

The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...

  • Publish Date: February 18, 2019
  • $1290
Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...

  • Publish Date: December 11, 2018
  • $1390